EW:NYE-Edwards Lifesciences Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 88.52

Change

0.00 (0.00)%

Market Cap

USD 18.35B

Volume

3.71M

Analyst Target

USD 86.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Edwards Lifesciences Corp technologies that treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.12 (+0.11%)

USD 196.14B
MDT Medtronic PLC

+0.06 (+0.07%)

USD 115.25B
STE STERIS plc

+0.34 (+0.14%)

USD 23.37B
ZBH Zimmer Biomet Holdings Inc

+1.21 (+1.14%)

USD 21.67B
SNN Smith & Nephew SNATS Inc

+0.29 (+0.95%)

USD 13.37B
GMED Globus Medical

+0.17 (+0.24%)

USD 9.42B
BIO Bio-Rad Laboratories Inc

+16.55 (+5.24%)

USD 9.32B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 8.85B
PEN Penumbra Inc

+4.74 (+2.54%)

USD 7.80B
GKOS Glaukos Corp

+1.19 (+0.94%)

USD 7.15B

ETFs Containing EW

CYBG:LSE VanEck Bionic Engineering.. 10.75 % 0.00 %

-0.13 (-0.84%)

N/A
CIB0:XETRA VanEck Bionic Engineering.. 8.36 % 0.00 %

+0.02 (+-0.84%)

USD 6.28M
UMDV:SW iShares US Medical Device.. 4.94 % 0.00 %

N/A

N/A
WHCS:SW iShares MSCI World Health.. 2.80 % 0.00 %

N/A

N/A
WELE:XETRA Amundi S&P 500 Equal Weig.. 0.59 % 0.00 %

+0.07 (+-0.84%)

N/A
HECO 0.00 % 0.95 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.26 (+-0.84%)

N/A
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

+2.38 (+-0.84%)

USD 0.24B
INAU 0.00 % 0.00 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-1.88 (-0.84%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.01 (+-0.84%)

N/A
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

+0.08 (+-0.84%)

USD 0.18B
CBUF:F iShares V Public Limited .. 0.00 % 0.00 %

-0.01 (-0.84%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.09% 70% C- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.09% 70% C- 85% B
Trailing 12 Months  
Capital Gain -2.82% 61% D- 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.82% 61% D- 22% F
Trailing 5 Years  
Capital Gain 37.43% 65% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.43% 65% D 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.25% 45% F 60% D-
Dividend Return 5.25% 45% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.97% 76% C+ 41% F
Risk Adjusted Return 20.21% 48% F 43% F
Market Capitalization 18.35B 88% B+ 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.30 70% 17%
Price/Book Ratio 8.17 16% 10%
Price / Cash Flow Ratio 58.52 12% 4%
Price/Free Cash Flow Ratio 30.33 12% 6%
Management Effectiveness  
Return on Equity 21.28% 100% 84%
Return on Invested Capital 19.57% 97% 87%
Return on Assets 12.05% 100% 95%
Debt to Equity Ratio 8.98% 95% 88%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.